Similarly, targetedinhibition of APOC3 was found to be associated with a reduced risk ofAAA and CAVS (OR: 0.387, 95% CI: 0.182–0.824, p = 0.014; OR: 0.540,95% CI: 0.351–0.829, p< 0.0055, respectively), while no protectiveeffect was noted for TAA, AD, and CAVS. Here, APOC3 is linked to Alzheimer disease.